Nicolaus Kroger

Summary

Affiliation: University of Hamburg
Country: Germany

Publications

  1. ncbi Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation
    Francis Ayuk
    Dept of Stem cell Transplantation, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Haematologica 93:1343-50. 2008
  2. ncbi Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany Electronic address
    Biol Blood Marrow Transplant 19:398-404. 2013
  3. ncbi Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome
    Nicolaus Kroger
    Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Blood 119:5632-9. 2012
  4. ncbi Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation
    Nicolaus Kroger
    Dept for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Haematologica 94:542-9. 2009
  5. ncbi Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome
    N Kroger
    Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 37:183-9. 2006
  6. ncbi Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Transfusion 44:104-10. 2004
  7. ncbi Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation
    Nicolaus Kroger
    University Hospital Hamburg Eppendorf, Germany
    Br J Haematol 148:323-31. 2010
  8. ncbi Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma
    Nicolaus Kroger
    Department of Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Biol Blood Marrow Transplant 16:861-4. 2010
  9. ncbi Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, Transplant Center, Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 12:159-68. 2006
  10. ncbi Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
    N Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 37:339-44. 2006

Detail Information

Publications118 found, 100 shown here

  1. ncbi Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation
    Francis Ayuk
    Dept of Stem cell Transplantation, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Haematologica 93:1343-50. 2008
    ..In vitro studies suggest that antithymocyte globulin, besides causing T-cell depletion, has strong anti-myeloma activity...
  2. ncbi Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany Electronic address
    Biol Blood Marrow Transplant 19:398-404. 2013
    ..These results suggest that auto-allo tandem SCT may overcome the negative prognostic effect of del(17p13) and/or t(4;14) and that achievement of molecular remission resulted in long-term freedom from disease...
  3. ncbi Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome
    Nicolaus Kroger
    Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Blood 119:5632-9. 2012
    ....
  4. ncbi Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation
    Nicolaus Kroger
    Dept for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Haematologica 94:542-9. 2009
    ..After successful treatment of malignant diseases, therapy-related myelodysplastic syndrome and acute myeloid leukemia have emerged as significant problems...
  5. ncbi Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome
    N Kroger
    Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 37:183-9. 2006
    ..Autologous transplantation may cure a substantial number of patients with treatment-related MDS/AML, especially if they are in CR1 and of younger age...
  6. ncbi Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Transfusion 44:104-10. 2004
    ..G-CSF given as split dose increased the harvested number of CD34+ cells in comparison to a once daily schedule, but the mechanism is poorly understood...
  7. ncbi Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation
    Nicolaus Kroger
    University Hospital Hamburg Eppendorf, Germany
    Br J Haematol 148:323-31. 2010
    ..02). We conclude that optimal donor selection is mandatory for a low non-relapse mortality and high relapse incidence, which remains a major concern, should be improved by including post-transplant strategies to upgrade remission status...
  8. ncbi Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma
    Nicolaus Kroger
    Department of Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Biol Blood Marrow Transplant 16:861-4. 2010
    ..Our data indicate that an intensified myeloablative conditioning regimen followed by allogeneic SCT can produce long-term survival and freedom from disease in patients with multiple myeloma who achieve CR...
  9. ncbi Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, Transplant Center, Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 12:159-68. 2006
    ..To analyze prognostic and predictive effects of immunohistochemical factors within a randomized study of high-dose versus standard-dose chemotherapy in high-risk breast cancer with >10 involved lymph nodes...
  10. ncbi Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
    N Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 37:339-44. 2006
    ..02). The treatment-related mortality at day 100 was 28%. The 2-year estimated overall and disease-free survival was 36-34%, respectively. No difference in survival was seen between unrelated and related SCT...
  11. ncbi Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation
    N Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg, Germany
    Ann Oncol 14:554-8. 2003
    ..To determine the incidence of secondary myelodysplasia (sMDS) or acute myeloid leukemia (AML) in node-positive breast cancer patients who received high-dose chemotherapy (HDCT) followed by autologous stem-cell support as adjuvant therapy...
  12. ncbi Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Exp Hematol 34:688-94. 2006
    ....
  13. ncbi [Allogenic stem cell transplantation following dose-reduced conditioning in patients with hematologic systemic diseases or solid tumors]
    N Kroger
    Knochenmarktransplantation, Universitatsklinikum Hamburg Eppendorf
    Ther Umsch 61:385-8. 2004
    ..Therefore, dose-reduced conditioning followed by allogeneic stem cell transplantation can be offered to older and more debilitated patients who were no candidates for standard allogeneic stem cell transplantation...
  14. ncbi Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Blood 104:3361-3. 2004
    ..The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus host disease...
  15. ncbi Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg, Germany
    Biol Blood Marrow Transplant 10:698-708. 2004
    ....
  16. ncbi HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen
    Nicolaus Kroger
    Department of Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Biol Blood Marrow Transplant 15:454-62. 2009
    ..013) (P = .004) and bad-risk disease (HR 1.975) (P < .001) were independent risk factors for DFS. In conclusion, pretransplant ATG allows allogeneic SCT from unrelated donors with HLA disparities...
  17. ncbi Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leuk Lymphoma 46:813-21. 2005
    ....
  18. ncbi Rabbit-IgG levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
    Haematologica 90:869B. 2005
  19. ncbi Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg, Hamburg, Germany
    Br J Haematol 129:631-43. 2005
    ..0001). We conclude that alemtuzumab produced less acute GvHD, but higher probability of relapse. The data implicated a major role of KIR-ligand mismatched transplantation in multiple myeloma...
  20. ncbi Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma
    Nicolaus Kroger
    Department for Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Exp Hematol 37:791-8. 2009
    ..To investigate post-transplant immunotherapy with escalating donor-lymphocyte infusions (DLI) and novel agents (thalidomide, bortezomib, and lenalidomide) to target complete remission (CR)...
  21. ncbi Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
    N Kroger
    Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
    Ann Hematol 82:336-42. 2003
    ....
  22. ncbi Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis
    Nicolaus Kroger
    Unit of Bone Marrow Transplantation, University Hospital Hamburg, D 20246 Hamburg, Germany
    Br J Haematol 128:690-7. 2005
    ..After a median follow-up of 22 months (range, 4-59), the 3-year estimated overall and disease-free survival was 84% (95% CI: 67-100%)...
  23. ncbi Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
    Nicolaus Kroger
    Center for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Blood 114:5264-70. 2009
    ..70; P = .02) and human leukocyte antigen-mismatched donor (hazard ratio = 3.04; P = .006) remained significant factors for survival. The study was registered at www.clinicaltrials.gov as #NCT 00599547...
  24. ncbi Stem cell transplantation from identical twins in patients with myelodysplastic syndromes
    N Kroger
    Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Bone Marrow Transplant 35:37-43. 2005
    ..6 (95% CI: 0.4-1.0; P=0.07). We conclude that twin transplantation in MDS/sAML is associated with a similar relapse risk, a lower TRM and a trend for better overall survival in comparison to transplantation from HLA-identical siblings...
  25. ncbi Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin
    N Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Ann Hematol 81:627-31. 2002
    ..We conclude that ATG plus cyclophosphamide is an effective conditioning regimen in patients with aplastic anemia undergoing stem cell transplantation with a low treatment-related mortality, resulting in an excellent outcome...
  26. ncbi Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Germany
    Blood 100:3919-24. 2002
    ....
  27. ncbi Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg, Hamburg, Germany
    Transplantation 82:1024-30. 2006
    ....
  28. ncbi Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with a
    N Kroger
    Bone Marrow Transplantation, University Hospital Hamburg, Department of Bone Marrow Transplantation, Pavlow University, St Petersburg, Russia
    Br J Haematol 113:1060-71. 2001
    ....
  29. ncbi Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors
    N Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Germany
    Ann Hematol 80:209-15. 2001
    ..ATG in unrelated stem cell transplantation reduces the risk of severe acute and chronic GvHD and of graft failure without an obvious increase of severe infection. Further follow-up is mandatory to determine the incidence of late relapse...
  30. ncbi Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation
    N Kroger
    Department for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leukemia 21:1851-8. 2007
    ....
  31. ncbi Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Blood 103:4056-61. 2004
    ..48; 95% CI, 1.19-5.17; P =.02), while patients with deletion 13q had a nearly 2 times higher risk of death (HR, 1.94; 95% CI, 0.95-3.98; P =.07) after dose-reduced allogeneic stem cell transplantation...
  32. ncbi Approaches to relapse after allogeneic stem cell transplantation
    Nicolaus Kroger
    Clinic for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Curr Opin Oncol 23:203-8. 2011
    ..In general, prognosis is poor for patients who relapsed to an allograft since effective treatment options are limited. Here, we review the available and upcoming treatment approaches for relapse...
  33. ncbi Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma
    N Kroger
    Bone Marrow Transplantation and Department of Clinical Chemistry, University Hospital Hamburg Eppendorf, and A K St Georg, Hamburg, Germany
    Br J Haematol 112:421-3. 2001
    ..host disease (GvHD) and limited or extensive chronic GvHD in each patient. We conclude that DLI induced further tumour reduction in patients with persistent disease after allografting for multiple myeloma...
  34. ncbi A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation
    N Kroger
    Department of Bone Marrow Transplantation, University of Hamburg, Germany
    Br J Haematol 111:761-5. 2000
    ....
  35. ncbi Choosing between stem cell therapy and drugs in myelofibrosis
    N Kroger
    Department of Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leukemia 22:474-86. 2008
    ..The potential for continued improvements in both medical and transplant therapy suggests that for the immediate future the optimal choices for an individual patient will remain potentially volatile and present complex decisions...
  36. ncbi Unrelated stem cell transplantation for patients with multiple myeloma
    Nicolaus Kroger
    Clinic for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Curr Opin Hematol 17:538-43. 2010
    ....
  37. ncbi Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
    Nicolaus Kroger
    Bone Marrow Transplantation, University Medical Center Hamburg Eppendorf, and Department of Hematology Oncology, University Hospital Regensburg, Germany
    Blood 109:1316-21. 2007
    ....
  38. ncbi Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis
    Nicolaus Kroger
    Department for Stem Cell Transplantation, University Medical Center, Hamburg Eppendorf, Martinistraße 52 D 20246, Hamburg, Germany
    Haematologica 96:291-7. 2011
    ..Bone marrow fibrosis in patients with myelodysplastic syndrome is associated with a poor outcome, but whether the outcome after allogeneic stem cell transplantation is related to the degree of bone marrow fibrosis is unknown...
  39. ncbi Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leuk Lymphoma 43:1391-4. 2002
    ..A prolonged follow-up of the donors is needed to rule out late toxicity of the donors...
  40. ncbi Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg, Hamburg, Germany
    Blood 100:755-60. 2002
    ..The tandem auto-allotransplant protocol is highly active and provides rapid engraftment with complete donor chimerism and tolerable toxicity...
  41. ncbi Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
    Nicolaus Kroger
    University Hospital Hamburg, Germany
    Br J Haematol 118:67-73. 2002
    ..The data showed a trend for a lower relapse probability of acute GvHD grade II-IV (24% vs 54%; P = 0.07), and for a higher relapse rate in patients with T cell-depleted grafts (62% vs 45%), suggesting a 'graft-versus-CMML effect'...
  42. ncbi Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, Transplant Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Exp Hematol 34:770-5. 2006
    ..3 mg/m(2) intravenously, days 1, 4, 8, and 11) after dose-reduced allogeneic stem cell transplantation (SCT) on toxicity, CD3(+) cells, graft-versus-host disease (GvHD), and response in patients with multiple myeloma...
  43. ncbi Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 24:3919-26. 2006
    ..To compare progression-free survival between single and tandem high-dose chemotherapy (HDT) followed by autologous stem-cell transplantation in chemotherapy-sensitive metastatic breast cancer patients...
  44. ncbi Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors
    Francis Ayuk
    Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany
    Exp Hematol 36:1047-54. 2008
    ..Allogeneic HSCT from matched unrelated and mismatched donors carries an increased risk of graft-vs-host disease (GVHD) and transplant-related mortality (TRM)...
  45. ncbi Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia
    Evgeny Klyuchnikov
    Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Germany
    Leuk Lymphoma 51:1450-63. 2010
    ..Thus, the evaluation of post-transplant immune reconstitution in patients with AML might improve risk stratification concerning either relapse or TRM and remains to be further explored...
  46. ncbi Second allogeneic stem cell transplantation in myeloid malignancies
    Maite Hartwig
    Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany
    Acta Haematol 122:185-92. 2009
    ..Efforts should concentrate on an optimization of conditioning strategies, immunosuppression and post-transplant surveillance for this specific situation...
  47. ncbi Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM)
    Nicolaus Kroger
    Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Germany
    Bone Marrow Transplant 31:973-9. 2003
    ..In vivo T-cell depletion with ATG resulted in a low rate of severe GvHD with low treatment-related mortality, and a substantial number of long-term survivors...
  48. ncbi Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation
    Francis Ayuk
    Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany
    Biol Blood Marrow Transplant 14:913-9. 2008
    ..A prospective randomized study comparing these 2 doses of ATG-F is warranted...
  49. ncbi Role of interleukin 16 in multiple myeloma
    Djordje Atanackovic
    Department of Medicine II, Oncology Hematology Stem Cell Transplantation, University Cancer Center Hamburg Hubertus Wald Tumorzentrum, University Medical Center Hamburg Eppendorf, Martinistrasse 52, Hamburg, Germany
    J Natl Cancer Inst 104:1005-20. 2012
    ..Interleukin 16 (IL-16) is involved in regulating the migration and proliferation of normal leukocytes. However, the role of IL-16 in human cancers, including multiple myeloma, is unclear...
  50. ncbi Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis
    Nicolaus Kroger
    Department of Stem Cell Transplantation, University Hospital Hamburg, Germany
    Exp Hematol 35:1719-22. 2007
    ..To investigate the effect of a busulfan/fludarabine-based reduced intensity conditioning followed by allogeneic stem cell transplantation on regression of bone marrow fibrosis in patients with myelofibrosis...
  51. ncbi CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation
    Djordje Atanackovic
    Department of Medicine II, Oncology Hematology, University Medical Center, Hamburg Eppendorf Martinistr 52, 20246 Hamburg, Germany
    Haematologica 93:423-30. 2008
    ....
  52. ncbi Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting
    Evgeny Klyuchnikov
    Department of Stem Cell Transplantation, University Cancer Centre Hamburg, Hamburg, Germany
    Br J Haematol 159:172-81. 2012
    ....
  53. ncbi Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia
    Bettina Wiedemann
    Interdisciplinary Clinic for Stem Cell Transplantation, University of Hamburg, Martinistrasse 52, Hamburg, Germany
    Exp Hematol 38:1261-71. 2010
    ..Chimerism is well-established for surveillance of acute myeloid leukemia (AML) patients after allogeneic hematopoietic stem cell transplantation (HSCT), but interpretation of the results and techniques is not standardized...
  54. ncbi A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome
    N Kroger
    Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Bone Marrow Transplant 28:643-7. 2001
    ....
  55. ncbi NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogenei
    Nicolaus Kroger
    Department for Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Martinstrasse 52, Hamburg, Germany
    Biol Blood Marrow Transplant 16:1187-211. 2010
    ....
  56. ncbi Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors
    Sunday Ocheni
    Department for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leuk Lymphoma 50:612-8. 2009
    ..We conclude that Pegfilgrastim ensured rapid neutrophil engraftment after unrelated allogeneic peripheral SCT, which was at least as effective as daily lenograstim...
  57. ncbi Autologous stem cell transplantation in myelodysplastic syndromes
    Theo de Witte
    Department of Hematology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands, and Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Semin Hematol 44:274-7. 2007
    ..Further development of precise prognostic classification systems, including an accurate evaluation of cytogenetic/molecular response to chemotherapy, is needed to develop a risk-adapted strategy for individual patients...
  58. ncbi Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation
    Ulrike Bacher
    Clinic for Stem Cell Transplantation, University of Hamburg, Germany
    Exp Hematol 37:135-42. 2009
    ..Nucleophosmin (NPM1) mutations, with their high frequency in AML, were suggested to represent suitable MRD markers, but so far no study has evaluated their usefulness in the posttransplantation period...
  59. ncbi The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients
    Yanran Cao
    Department of Internal Medicine II Oncology Hematology Stem Cell Transplantation, University Cancer Center Hamburg Hubertus Wald Tumorzentrum, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Exp Hematol 38:860-7. 2010
    ..We aimed at answering the question which cytokines, chemokines, and growth factors are typically found in the BM of untreated MM patients as well as in MM patients after allogeneic stem cell transplantation (alloSCT)...
  60. ncbi Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
    Djordje Atanackovic
    Center of Oncology, Department of Medicine II, Oncology Hematology Stem Cell Transplantation, University Cancer Center Hamburg Hubertus Wald Tumorzentrum, Hamburg, Germany
    Haematologica 96:1512-20. 2011
    ..We, therefore, investigated functionally relevant immunoreceptors specifically associated with myeloma cells as well as their clonogenic precursors...
  61. ncbi Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis
    Tanja Stahl
    Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Germany
    Leuk Lymphoma 51:1837-43. 2010
    ....
  62. ncbi Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
    Haefaa Alchalby
    Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Martinistrasse 52, Hamburg, Germany
    Blood 116:3572-81. 2010
    ..03). We conclude that JAK2V617F-mutated status, but not allele frequency, resulted in an improved survival and rapid clearance after allografting reduces the risk of relapse...
  63. ncbi An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body
    Yanran Cao
    Department of Internal Medicine II Oncology, Haematology, Stem Cell Transplantation, University Cancer Centre Hamburg Hubertus Wald Tumorzentrum, Hamburg, Germany
    J Immunol Methods 358:56-65. 2010
    ..In the framework of our current study we set out to develop an optimized assay for the quantification of antigen-specific B cells in different compartments of the human body...
  64. ncbi Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation
    Natalja Fehse
    Bone Marrow Transplantation, University Hospital Eppendorf, Hamburg, Germany
    J Hematother Stem Cell Res 12:237-42. 2003
    ..We observed impaired immune reconstitution in the ATG group in comparison with the non-ATG group, indicating a significant influence of ATG on immune recovery for several months after BMT...
  65. ncbi Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients
    N Kroger
    Department of Bone Marrow Transplantation, University of Hamburg, Hamburg, Germany
    Bone Marrow Transplant 32:1153-7. 2003
    ..She achieved CR after induction therapy, but relapsed and expired 28 months after diagnosis of AML. sAML after mitoxantrone-based HDCT is a possible, but rare complication in breast cancer patients...
  66. ncbi Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma
    Djordje Atanackovic
    Department of Oncology Hematology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 15:1343-52. 2009
    ....
  67. ncbi Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation
    Evgeny Klyuchnikov
    Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Biol Blood Marrow Transplant 17:374-83. 2011
    ..Automated enrichment of CD4(+) by magnetic cell sorting provides an efficient and rapid method for processing donor lymphocytes. Additional studies should further investigate this approach in terms of efficacy and the risk of GVHD...
  68. ncbi Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
    Djordje Atanackovic
    Department of Oncology Hematology, Institute for Biochemistry and Molecular Biology, University Medical Center Hamburg Eppendorf, Germany
    Blood 109:1103-12. 2007
    ..Immune responses induced by alloSCT could be boosted by active CT antigen-specific immunotherapy, which might help to achieve long-lasting remissions in patients with MM...
  69. ncbi Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny
    Irene Cavattoni
    Interdisciplinary Clinic for Stem Cell Transplantation, University of Hamburg, Germany
    Leuk Lymphoma 51:1530-5. 2010
    ..Post-transplant prevention strategies and treatment to control advanced infection in this setting are discussed...
  70. ncbi Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma
    Caroline Pabst
    Department of Oncology Hematology Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Exp Mol Pathol 89:175-81. 2010
    ..013). Our results, therefore, suggest that expression of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of myeloma patients can be used for diagnostic, prognostic, as well as immunotherapeutic purposes...
  71. ncbi Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
    G Schilling
    Department of Oncology and Hematology, Medical Clinic II, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leukemia 22:1250-5. 2008
    ..Translocation t(4;14) might be overcome by allogeneic HSCT, which will have implication for risk-adapted strategies...
  72. ncbi Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients
    N Kroger
    Bone Marrow Transplantation, University Hospital Hamburg, Germany
    Bone Marrow Transplant 27:349-54. 2001
    ..Longer follow-up is necessary to determine the late relapse rate and late toxicity...
  73. ncbi Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia
    Tim Luetkens
    Department of Oncology and Hematology, Center of Oncology, Hamburg, Germany
    Leuk Res 34:1647-55. 2010
    ..However, a broad picture of the expression of CT antigens and associated humoral immune responses in chronic myeloid leukemia (CML) is still missing...
  74. ncbi Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes
    Ulrike Bacher
    Interdisciplinary Clinic for Stem Cell Transplantation, University Cancer Center Hamburg, Hamburg, Germany
    Biol Blood Marrow Transplant 16:1-11. 2010
    ..Consequently, in the near future, risk stratification in MDS might incorporate additional diagnostic tools and categorization systems aimed at improving the timing and indication for SCT in this complex disorder...
  75. ncbi Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies
    Francis Ayuk
    Department of Bone Marrow Transplantation, University Medical Center Hamburg Eppendorf, D 20246 Hamburg, Germany
    Anticancer Res 29:1355-60. 2009
    ..The cytotoxic effects of 4 ATG preparations (Thymoglobulin, ATG-Fresenius, Lymphoglobulin and ATGAM) in hematological malignancies were compared...
  76. ncbi Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells
    Francis A Ayuk
    Department of Bone Marrow Transplantation, University Medical Center Hamburg Eppendorf, Germany
    Exp Hematol 33:1531-6. 2005
    ..Because both agents have been reported to induce depletion of B cells, we sought to investigate their cytotoxic activity on myeloma cells...
  77. ncbi Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation
    J Dahlke
    Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 37:155-63. 2006
    ..56, 95% CI: 0.33-0.98, P=0.042), negative CMV status of the patient (RR: 0.57, 95% CI: 0.36-0.90, P = 0.015). Unrelated stem cell transplantation for high-risk ALL patients with no HLA-compatible family donor is justifiable...
  78. ncbi ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)
    A R Zander
    Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Germany
    Bone Marrow Transplant 32:355-61. 2003
    ..01 and P=0.03) and led to a significant better overall survival (70 vs 57%, P=0.03). We concluded that a prospective randomized study is needed to evaluate the definite role of ATG in hemopoietic stem cell transplantation...
  79. ncbi Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up
    A R Zander
    Center of Oncology, Clinic for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Ann Oncol 19:1082-9. 2008
    ..With a follow-up of 6 years, there was a trend in favor of HD-CT with respect to EFS not being significant. A proper meta-analysis needs to be undertaken for an evaluation of subgroups of patients who might benefit from HD-CT...
  80. ncbi Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up
    A A Oyekunle
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 37:45-50. 2006
    ..We conclude that patients with refractory leukemia can benefit from allogeneic BMT, especially with < or =20% marrow blast...
  81. ncbi Disseminated breast cancer cells prior to and after high-dose therapy
    W H Krüger
    Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany
    J Hematother Stem Cell Res 10:681-9. 2001
    ..However, further research is necessary to identify distinct cell populations with the potentially capacity to metastasize...
  82. ncbi Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro
    R Jung
    Department of Clinical Chemistry, University Hospital Eppendorf, Hamburg, Germany
    Br J Cancer 78:1194-8. 1998
    ..These factors have to be considered in future applications of RT-PCR for the detection of minimal residual disease...
  83. ncbi In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors
    N Kroger
    Bone Marrow Transplantation, University Hospital, Hamburg Eppendorf, Martinistrasse 52, D 20246, Hamburg, Germany
    Bone Marrow Transplant 29:683-9. 2002
    ..ATG as part of the conditioning regimen leads to a significant reduction in GVHD without increase of relapse in patients with myeloid leukemia after stem cell transplantation from HLA-related donors...
  84. ncbi Detection of virulence-associated genes not useful for discriminating between invasive and commensal Staphylococcus epidermidis strains from a bone marrow transplant unit
    Holger Rohde
    Institut für Infektionsmedizin, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    J Clin Microbiol 42:5614-9. 2004
    ..epidermidis strains. The dynamics of S. epidermidis populations reveal that detection of icaADBC and mecA is not suitable for discriminating invasive from contaminating S. epidermidis strains...
  85. ncbi Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells
    Djordje Atanackovic
    Department of Medicine II, Oncology Hematology, University Medical Center, Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
    Haematologica 95:785-93. 2010
    ..Surprisingly, the biological role of cancer-testis genes in myeloma remains poorly understood...
  86. ncbi Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation
    Sunday Ocheni
    Clinic for Stem Cell Transplantation, University Cancer Centre Hamburg, Hamburg, Germany
    Leuk Lymphoma 50:551-8. 2009
    ..Research should focus on prospective studies aiming to improve treatment of extramedullary relapse in stem cell recipients with CML with a special focus on the role of second generation tyrosine kinase inhibitors...
  87. ncbi Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia
    Djordje Atanackovic
    Center of Oncology, Department of Internal Medicine II, Oncology Hematology Stem Cell Transplantation, University Cancer Center Hamburg, Germany
    Am J Hematol 86:918-22. 2011
    ..Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2...
  88. ncbi High-dose therapy for breast cancer - a case of suspended animation
    Axel R Zander
    University Hospital Hamburg Eppendorf, Hamburg Eppendorf, Germany
    Acta Haematol 114:248-54. 2005
    ..It is further necessary to look at the biology of breast cancer in the context of high-dose chemotherapy studies...
  89. ncbi Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia
    Francis A Ayuk
    Department of Bone Marrow Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Leuk Res 32:1200-6. 2008
    ..ATGs however, contain antibodies targeting antigens expressed on various hematopoietic cells including B cells...
  90. ncbi Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma
    Francis Ayuk
    University Medical Center Hamburg Eppendorf, Germany
    Ann Hematol 88:401-4. 2009
    ..This review discusses available data demonstrating the cytotoxic effects of ATGs and envisages a possible new role of these polyclonal antibodies in the therapy of hematological malignancies...
  91. ncbi Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors
    N Kroger
    Department of Bone Marrow Transplantation, University of Hamburg, Germany
    Bone Marrow Transplant 29:727-30. 2002
    ..Administering G-CSF at a dosage of 8 microg/kg twice daily leads to a higher CD34(+) cell yield than a dosage of 2 x 5 microg/kg, but is associated with increased toxicity and higher cost...
  92. ncbi [Unrelated donor stem cell transplantation in children: low toxicity using a GvHD-prophylaxis regimen with CSA, MTX, metronidazole,iv-immunoglobulin and ATG]
    F Graf Finckenstein
    Universitatsklinikum Hamburg Eppendorf, Klinik, Germany
    Klin Padiatr 214:206-11. 2002
    ..On the other hand an optimal balance with immunocompetence of the transplanted bone marrow is desirable in order to prevent graft failure, infection and, in the case of leukaemic diseases, potentially control the underlying disease...
  93. ncbi Immunomagnetic tumor cell selection--implications for the detection of disseminated cancer cells
    W Kruger
    Bone Marrow Transplantation Center, Department of Transfusion Medicine, University Hospital Eppendorf, Hamburg, Germany
    Transfusion 40:1489-93. 2000
    ..Molecular methods such as cytokeratin-19 RT-PCR are about 10 times as sensitive, but they are hampered by interference such as illegitimate gene expression...
  94. ncbi Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation
    M Weber
    Department of Internal Medicine II and Bone Marrow Transplantation Unit, University Hospital Hamburg-Eppendorf, Martinistrasse 52, Germany
    Bone Marrow Transplant 31:817-22. 2003
    ..We conclude that ATG-F can induce nonovert DIC in patients receiving antithymocyte globulin as part of their conditioning regimen for HSCT...
  95. ncbi Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation
    B Fehse
    Bone Marrow Transplantation Center, University Hospital Eppendorf, Hamburg, Germany
    J Hematother Stem Cell Res 10:419-25. 2001
    ..In conclusion, quantitative Y chromosome-specific PCR is a promising approach for monitoring the extent of chimerism in blood and other tissues after sex-mismatched hematopoietic stem cell transplantation (HSCT) or organ transplantation...
  96. ncbi Influence of preharvest tumor cell contamination in bone marrow or blood does not predict resultant tumor cell contamination of granulocyte colony-stimulating factor mobilized stem cells
    W Kruger
    Marrow Transplantation Center, University Hospital Eppendorf, 20246 Hamburg, Germany
    J Hematother Stem Cell Res 10:303-7. 2001
    ..The tumor cell contamination of a stem cell harvest cannot be safely predicted by a preceding blood or marrow analysis...
  97. ncbi Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients
    M Dürken
    Abteilung für Pädiatrische Onkologie und Hämatologie, Abteilung für Knochenmarktransplantation, Hamburg, Germany
    Br J Haematol 106:1052-8. 1999
    ..Three patients show slight to moderate development delay. These results indicate that in HLH, BMT from matched unrelated donors should be performed. Incomplete resolution of disease activity need not impede a successful outcome...
  98. ncbi High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial
    A R Zander
    Transplant Center, University Hospital Hamburg Eppendorf, Hamburg, Germany
    J Clin Oncol 22:2273-83. 2004
    ....
  99. ncbi Tumour cell detection in G-CSF mobilised stem cell harvests of patients with breast cancer
    W Kruger
    Bone Marrow Transplantation Centre, Department of Haematology Oncology, University Hospital Eppendorf, Hamburg, Germany
    Med Oncol 16:17-22. 1999
    ..To allow a comparison of different studies dealing with cancer cell contamination in stem cells, standardisation of assays is necessary...
  100. ncbi Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM
    M Lioznov
    Clinic for Stem Cell Transplantation, University Medical Centre Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 42:121-8. 2008
    ..We, therefore, conclude that PBSC grafts become much more sensitive to cryopreservation after transport and/or storage. Importantly, the engraftment potential of frozen HSC grafts may reliably be predicted by measuring ALDH activity...
  101. ncbi The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004
    Ulrike Bacher
    Interdisziplinäre Klinik für Stammzelltransplantation, Universitäres Cancer Center Hamburg UCCH, Martinistr 52, 20246 Hamburg, Germany
    Ann Hematol 88:1237-47. 2009
    ..This study demonstrates that allo-SCT still has an important role in advanced CML, which emphasizes the need for optimized transplantation strategies for these high-risk patients...